Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Craig shouldn’t be alive to tell his story, in fact, he should have died three years ago, but a wonder drug dragged him back ...

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to ...

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for ...

The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug ...

Study Rundown: Many patients with localized, high-risk soft tissue sarcomas develop metastatic disease. Immunotherapy, such ...

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Alpha Tau will also host an R&D Update Day on Monday, January 27, 2025 at 11am ET, during which the Company will review the new data shared at the symposium and additional data from the Company’s ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...